Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.

Date publication

septembre 2024

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RIOS Maria

Tous les auteurs :
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Le Cesne A, Balleyguier C, Archambaud B, Duffaud F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39231341

Résumé

The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.

Mots clés

Humans, Trabectedin, administration & dosage, Doxorubicin, administration & dosage, Female, Leiomyosarcoma, drug therapy, Middle Aged, Male, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Progression-Free Survival, Uterine Neoplasms, drug therapy, Adult, Maintenance Chemotherapy, Kaplan-Meier Estimate, Soft Tissue Neoplasms, drug therapy, Survival Analysis, Dioxoles, adverse effects

Référence

N Engl J Med. 2024 09 5;391(9):789-799